Summit Therapeutics
Summit Therapeutics Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in the discovery, development, and commercialization of novel antibiotics aimed at treating serious infectious diseases. The company focuses on addressing Clostridium difficile infection (CDI) with its lead product candidate, ridinilazole, which is currently undergoing Phase III clinical trials. Additionally, Summit is developing the DDS-01 series to combat infections caused by Neisseria gonorrhoeae and the DDS-04 series targeting Enterobacteriaceae. With operations in the United States and Europe, Summit Therapeutics aims to establish new standards of care for patients while creating value for payors and healthcare providers. Founded in 2003, the company is committed to advancing innovative treatments for infectious diseases.
Discuva
Acquisition in 2017
Discuva is a Cambridge-based company focused on the discovery of next-generation antibiotics to combat drug-resistant bacterial infections. Established to fill significant gaps in the current antibiotic treatment landscape, Discuva utilizes proprietary methods derived from recent advances in genomic technologies. The company aims to develop targeted antibiotics specifically designed to address emerging and highly drug-resistant pathogens, thereby safeguarding public health against the growing threat posed by these infections. With a management team experienced in the pharmaceutical and biotech sectors, Discuva is poised to make substantial contributions to the field of antimicrobial treatment.
DanioLabs
Acquisition in 2007
DanioLabs Ltd. discovers and develops therapeutics for neurological, ophthalmologic, metabolic, and gastrointestinal diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.